Detecting earlier stages of amyloid deposition using PET in cognitively normal elderly adults
Abstract
Objective
To examine the feasibility of using cross-sectional PET to identify cognitive decliners among β-amyloid (Aβ)-negative cognitively normal (CN) elderly adults.
Methods
We determined the highest Aβ-affected region by ranking baseline and accumulation rates of florbetapir-PET regions in 355 CN elderly adults using 18F-florbetapir-PET from the Alzheimer's Disease Neuroimaging Initiative (ADNI). The banks of the superior temporal sulcus (BANKSSTS) were found as the highest Aβ-affected region, and Aβ positivity in this region was defined as above the lowest boundary of BANKSSTS standardized uptake value ratio of Aβ+ (ADNI-defined COMPOSITE region) CN individuals. The entire CN cohort was divided as follows: stage 0, BANKSSTS−COMPOSITE−; stage 1, BANKSSTS+COMPOSITE−; and stage 2, BANKSSTS+COMPOSITE+. Linear mixed-effect (LME) models investigated subsequent longitudinal cognitive change, and 18F-flortaucipir (FTP)-PET was measured 4.8 ± 1.6 years later to track tau deposition.
Results
LME analysis revealed that individuals in stage 1 (n = 64) and stage 2 (n = 99) showed 2.5 (p < 0.05) and 4.8 (p < 0.001) times faster memory decline, respectively, than those in stage 0 (n = 191) over >4 years of mean follow-up. Compared to stage 0, both stage 1 (p < 0.05) and stage 2 (p < 0.001) predicted higher FTP in entorhinal cortex.
Conclusions
Nominally Aβ− CN individuals with high Aβ in BANKSSTS are at increased risk of cognitive decline, probably showing an earlier stage of Aβ deposition. Our findings may help elucidate the association between brain Aβ accumulation and cognition in Aβ− CN cohorts.
Classification of evidence
This study provides Class II evidence that in elderly CN individuals those with high PET-identified superior temporal sulcus Aβ burden have an increased risk of cognitive decline.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Jack CR, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013;12:207–216.
2.
Roberts RO, Aakre JA, Kremers WK, et al. Prevalence and outcomes of amyloid positivity among persons without dementia in a longitudinal, population-based setting. JAMA Neurol 2018;75:970.
3.
Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 2014;370:322–333.
4.
Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 2014;370:311–321.
5.
Egan MF, Kost J, Tariot PN, et al. Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease. N Engl J Med 2018;378:1691–1703.
6.
Liu E, Schmidt ME, Margolin R, et al. Amyloid-β 11 C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials. Neurology 2015;85:692–700.
7.
Landau SM, Horng A, Jagust WJ. Memory decline accompanies subthreshold amyloid accumulation. Neurology 2018;90:e1452–e1460.
8.
Farrell ME, Chen X, Rundle MM, Chan MY, Wig GS, Park DC. Regional amyloid accumulation and cognitive decline in initially amyloid-negative adults. Neurology 2018;91:e1809–e1821.
9.
Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010;9:363–372.
10.
Villemagne VL, Pike KE, Chételat G, et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol 2011;69:181–192.
11.
Wong DF, Rosenberg PB, Zhou Y, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (flobetapir F 18). J Nucl Med 2010;51:913–920.
12.
Barthel H, Gertz HJ, Dresel S, et al. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol 2011;10:424–435.
13.
Villain N, Chételat G, Grassiot B, et al. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. Brain 2012;135:2126–2139.
14.
Guo T, Brendel M, Grimmer T, Rominger A, Yakushev I. Predicting regional pattern of longitudinal β-amyloid accumulation by baseline PET. J Nucl Med 2017;58:639–645.
15.
Guo T, Dukart J, Brendel M, Rominger A, Grimmer T, Yakushev I. Rate of β-amyloid accumulation varies with baseline amyloid burden: implications for anti-amyloid drug trials. Alzheimers Dement 2018;14:1387–1396.
16.
Landau SM, Mintun MA, Joshi AD, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol 2012;72:578–586.
17.
Whittington A, Sharp DJ, Gunn RN. Spatiotemporal distribution of β-amyloid in Alzheimer disease is the result of heterogeneous regional carrying capacities. J Nucl Med 2018;59:822–827.
18.
Landau SM, Fero A, Baker SL, et al. Measurement of longitudinal-amyloid change with 18F-florbetapir PET and standardized uptake value ratios. J Nucl Med 2015;56:567–574.
19.
Desikan RS, Ségonne F, Fischl B, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 2006;31:968–980.
20.
Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 1995;57:289–300.
21.
Villeneuve S, Rabinovici GD, Cohn-Sheehy BI, et al. Existing Pittsburgh compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain 2015;138:2020–2033.
22.
Crane PK, Carle A, Gibbons LE, et al. Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Brain Imaging Behav 2012;6:502–516.
23.
Gibbons LE, Carle AC, Mackin RS, et al. A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging Behav 2012;6:517–527.
24.
Maass A, Landau S, Baker SL, et al. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease. Neuroimage 2017;157:448–463.
25.
Buckner RL, Head D, Parker J, et al. A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume. Neuroimage 2004;23:724–738.
26.
Palmqvist S, Schöll M, Strandberg O, et al. Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nat Commun 2017;8:1214.
27.
Gordon BA, Blazey TM, Su Y, et al. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. Lancet Neurol 2018;17:241–250.
28.
Gómez-Isla T, Hollister R, West H, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 1997;41:17–24.
29.
Killiany RJ, Gomez-Isla T, Moss M, et al. Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. Ann Neurol 2000;47:430–439.
30.
Grothe MJ, Barthel H, Sepulcre J, Dyrba M, Sabri O, Teipel SJ. In vivo staging of regional amyloid deposition. Neurology 2017;89:2031–2038.
31.
Donohue MC, Sperling RA, Salmon DP, et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol 2014;71:961–970.
32.
Pietrzak RH, Lim YY, Neumeister A, et al. Amyloid-β, anxiety, and cognitive decline in preclinical Alzheimer disease a multicenter, prospective cohort study. JAMA Psychiatry 2015;72:284–291.
33.
Clark LR, Racine AM, Koscik RL, et al. Beta-amyloid and cognitive decline in late middle age: findings from the Wisconsin Registry for Alzheimer's Prevention study. Alzheimers Dement 2016;12:805–814.
34.
Petersen RC, Wiste HJ, Weigand SD, et al. Association of elevated amyloid levels with cognition and biomarkers in cognitively normal people from the community. JAMA Neurol 2016;73:85–92.
35.
Mormino EC, Papp KV, Rentz DM, et al. Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β. Alzheimers Dement (Amst) 2017;13:1004–1012.
36.
Baker JE, Lim YY, Pietrzak RH, et al. Cognitive impairment and decline in cognitively normal older adults with high amyloid-β: a meta-analysis. Alzheimers Dement (Amst) 2018;6:108–121.
37.
Donohue MC, Sperling RA, Petersen R, Sun CK, Weiner MW, Aisen PS. Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons. JAMA 2017;317:2305.
38.
Farrell ME, Kennedy KM, Rodrigue KM, et al. Association of longitudinal cognitive decline with amyloid burden in middle-aged and older adults: evidence for a dose-response relationship. JAMA Neurol 2017;74:830–838.
39.
Zhao Y, Tudorascu DL, Lopez OL, et al. Amyloid β deposition and suspected non-Alzheimer pathophysiology and cognitive decline patterns for 12 years in oldest old participants without dementia. JAMA Neurol 2018;75:88–96.
40.
Lim YY, Snyder PJ, Pietrzak RH, et al. Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: introducing the Z-scores of attention, verbal fluency, and episodic memory for nondemented older adults composite score. Alzheimers Dement (Amst) 2016;2:19–26.
41.
Resnick SM, Sojkova J, Zhou Y, et al. Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology 2010;74:807–815.
42.
Leal SL, Lockhart SN, Maass A, Bell RK, Jagust WJ. Subthreshold amyloid predicts tau deposition in aging. J Neurosci 2018;38:4482–4489.
43.
Egan MF, Kost J, Voss T, et al. Randomized trial of verubecestat for prodromal Alzheimer's disease. N Engl J Med 2019;380:1408–1420.
44.
Hanseeuw BJ, Betensky RA, Mormino EC, et al. PET staging of amyloidosis using striatum. Alzheimers Dement 2018;14:1281–1292.
45.
Palmqvist S, Mattsson N, Hansson O. Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography. Brain 2016;139:1226–1236.
46.
Racine AM, Koscik RL, Nicholas CR, et al. Cerebrospinal fluid ratios with Aβ 42 predict preclinical brain β-amyloid accumulation: Alzheimer's dement diagnosis. Alzheimers Dement (Amst) 2016;2:27–38.
47.
Mattsson N, Insel PS, Donohue M, et al. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease. Brain 2015;138:772–783.
48.
Palmqvist S, Zetterberg H, Blennow K, et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol 2014;71:1282–1289.
49.
Toledo JB, Bjerke M, Da X, et al. Nonlinear association between cerebrospinal fluid and florbetapir F-18 β-amyloid measures across the spectrum of Alzheimer disease. JAMA Neurol 2015;72:571–581.
Information & Authors
Information
Published In
Copyright
© 2020 American Academy of Neurology.
Publication History
Received: April 29, 2019
Accepted: November 14, 2019
Published online: March 18, 2020
Published in print: April 7, 2020
Disclosure
T. Guo reports no disclosures relevant to the manuscript. S.M. Landau has served as a consultant to Cortexyme and NeuroVision. W.J. Jagust has served as a consultant to Genentech, Novartis, Bioclinica, and Biogen. Go to Neurology.org/N for full disclosures.
Study Funding
Data collection and sharing for this project were funded by the ADNI (NIH grant U01 AG024904) and Department of Defense ADNI (Department of Defense award W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, by the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc; Biogen; Bristol-Myers Squibb Co; CereSpir, Inc; Eisai Inc; Elan Pharmaceuticals, Inc; Eli Lilly and Co; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc; Fujirebio; GE Healthcare; IXICO Ltd; Janssen Alzheimer Immunotherapy Research & Development, LLC; Johnson & Johnson Pharmaceutical Research & Development LLC; Lumosity; Lundbeck; Merck & Co, Inc; Meso Scale Diagnostics, LLC; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corp; Pfizer Inc; Piramal Imaging; Servier; Takeda Pharmaceutical Co; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the NIH (fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.
Authors
Metrics & Citations
Metrics
Citation information is sourced from Crossref Cited-by service.
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Longitudinal relationships between Aβ and tau to executive function and memory in cognitively normal older adults, Neurobiology of Aging, 145, (32-41), (2025).https://doi.org/10.1016/j.neurobiolaging.2024.10.004
- Convergent Multimodal Imaging Abnormalities in the Dorsal Precuneus in Subjective Cognitive Decline, Journal of Alzheimer's Disease, 101, 2, (589-601), (2024).https://doi.org/10.3233/JAD-231360
- Pathophysiology characterization of Alzheimer’s disease in South China’s aging population: for the Greater-Bay-Area Healthy Aging Brain Study (GHABS), Alzheimer's Research & Therapy, 16, 1, (2024).https://doi.org/10.1186/s13195-024-01458-z
- Astrocyte reactivity is associated with tau tangle load and cortical thinning in Alzheimer’s disease, Molecular Neurodegeneration, 19, 1, (2024).https://doi.org/10.1186/s13024-024-00750-8
- From teeth to brain: dental caries causally affects the cortical thickness of the banks of the superior temporal sulcus, BMC Oral Health, 24, 1, (2024).https://doi.org/10.1186/s12903-024-03899-2
- Retinal Microvasculature Causally Affects the Brain Cortical Structure: A Mendelian Randomization Study, Ophthalmology Science, 4, 6, (100465), (2024).https://doi.org/10.1016/j.xops.2024.100465
- Trajectories of amyloid beta accumulation – Unveiling the relationship with APOE genotype and cognitive decline, Neurobiology of Aging, 139, (44-53), (2024).https://doi.org/10.1016/j.neurobiolaging.2024.03.007
- Spatial transcriptomic patterns underlying amyloid-β and tau pathology are associated with cognitive dysfunction in Alzheimer’s disease, Cell Reports, 43, 2, (113691), (2024).https://doi.org/10.1016/j.celrep.2024.113691
- [18F]-D3FSP β-amyloid PET imaging in older adults and alzheimer’s disease, European Journal of Nuclear Medicine and Molecular Imaging, 51, 13, (3990-4000), (2024).https://doi.org/10.1007/s00259-024-06835-2
- The ADNI PET Core at 20, Alzheimer's & Dementia, (2024).https://doi.org/10.1002/alz.14165
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.